The study and its comparison
Sixty-seven children aged three to six with mild-to-moderate autism entered a randomized study. Both groups received occupational and speech therapy; one also received carnosine. Sixty-three completed two months. [1]
The investigators found no significant between-group differences in the measured autism-related, sleep-screening or gastrointestinal scores. Thus the supplement did not demonstrate added benefit under the tested conditions. [1]
What the finding establishes
The short follow-up and small sample limit precision, and the abstract does not establish a matched placebo or complete masking. Funding and conflicts were not established from the retrieved record. A proposed antioxidant or neural role is not a substitute for improved outcomes, and the study does not support stopping useful developmental services in favor of supplementation. [1]
A hypothetical distinction
Imagine both groups receive supportive services and adding a supplement changes no measured outcome. The added benefit remains unproven.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- Effect of L-Carnosine as adjunctive therapy in the management of children with autism spectrum disorder: a randomized controlled study.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.